Immunotherapy in Allergic Rhinitis: It’s Effect on the Immune System and Clinical Symptoms

  • Samaneh Kouzegaran Allergy Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad
  • Mohammad Ali Zamani Pediatric Department, Shahrekord University of Medical Sciences, Shahrekord
  • Reza Faridhosseini Allergy Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad
  • Houshang Rafatpanah Immunology Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad
  • Abdolrahim Rezaee Immunology Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad
  • Hadis Yousefzadeh Immunology Research Center, Student Research Committee, School of Medicine, Mashhad University of Medical Sciences, Mashhad
  • Rahman Movahed Otorhinolaryngology-Head & Neck Surgery, Sinus and Surgical Endoscopic Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad
  • Farahzad Jabbari Azad Allergy Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad
  • Hooman Tehrani Allergy Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad
Keywords: Allergic rhinitis, Subcutaneous Immunotherapy, Cytokine

Abstract

BACKGROUND: Allergic rhinitis is one of the most common allergic diseases and characterised by sneezing, rhinorrhea, nasal congestion and nasopharyngeal itching. Subcutaneous immunotherapy (SCIT) for specific allergens is an effective treatment and induces the inhibitory effect of T regulatory lymphocytes and decreases clinical symptoms in allergic rhinitis.

AIM: In this study effect of subcutaneous immunotherapy with specific allergens on clinical symptoms and T regulatory and T Helper cells cytokines, in patients with allergic rhinitis are evaluated.

METHODS: In this study, 30 patients with moderate to severe allergic rhinitis according to clinical criteria and positive skin prick test for aeroallergens were selected and treated by SCIT. Clinical symptoms and T cells cytokines IL4, IL17, IFN gamma, TGF beta, GITR, FOXP3 and IL-10 (by RT-PCR) were evaluated before and one year after initiation of treatment.

RESULTS: Thirty (30) patients with allergic rhinitis at age range 15-45 years old were treated by SCIT, and 23 (14 female, 9 male) patients continued the study, and 7 patients did not continue treatment. After immunotherapy, clinical symptoms decreased significantly. The specific cytokines TGF beta and IL10 levels increased and changes were statistically significant. (Respectively P = 0.013 and P = 0.05) The IL17 level was also increased, but not statistically significant. (P = 0.8) IFN gamma, IL4, GITR, FOXP3, all decreased, but the changes were not statistically significant (P > 0.05).

CONCLUSION: Subcutaneous Immunotherapy for specific allergens decreases clinical symptoms in patients with allergic rhinitis and induces tolerance in T lymphocytes, especially by increasing T regulatory cells cytokines, TGF beta and IL10.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Corren J, Baroody F, Pawankar R. Allergic and non allergic rhinitis. In: Adkinson Jr NF, Bochner BS, Burks AW, Busse WW, Holgate ST, Lemanske Jr RF, et al., editors. Middleton's allergy: principles and practice. 1.8 ed. USA: Elsevier Health Sciences, 2014:664-85.

Jutel M, Akdis M, Budak F, Aebischer-Casaulta C, Wrzyszcz M, Blaser K, et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol. 2003; 33(5):1205-14. https://doi.org/10.1002/eji.200322919 PMid:12731045

Ciprandi G, De Amici M, Negrini S, Marseglia G, Tosca MA. TGF-β and IL-17 serum levels and specific immunotherapy. International immunopharmacology. 2009; 9(10):1247-9. https://doi.org/10.1016/j.intimp.2009.07.004 PMid:19622397

Akdis CA, Akdis M. Mechanisms and treatment of allergic disease in the big picture of regulatory T cells. Journal of Allergy and Clinical Immunology. 2009; 123(4):735-46. https://doi.org/10.1016/j.jaci.2009.02.030 PMid:19348912

Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. Journal of Allergy and Clinical Immunology. 2004; 113(6):1025-34. https://doi.org/10.1016/j.jaci.2004.03.024 PMid:15208578

Ziegler SF, Buckner JH. FOXP3 and the regulation of Treg/Th17 differentiation. Microbes and Infection. 2009; 11(5):594-8. https://doi.org/10.1016/j.micinf.2009.04.002 PMid:19371792 PMCid:PMC2728495

Farid R, Ghasemi R, Baradaran-Rahimi M, Jabbari F, Ghaffari J, Rafatpanah H. Evaluation of six years allergen immunotherapy in allergic rhinitis and allergic asthma. Iranian Journal of Allergy, Asthma and Immunology. 2006; 5(1):29-31. PMid:17242501

Roncarolo MG, Bacchetta R, Bordignon C, Narula S, Levings MK. Type 1 T regulatory cells. Immunological reviews. 2001; 182(1):68-79. https://doi.org/10.1034/j.1600-065X.2001.1820105.x PMid:11722624

Blaiss MS, editor Allergic rhinitis: Direct and indirect costs. Allergy and Asthma Proceedings; OceanSide Publications, Inc., 2010. PMCid:PMC2824441

Calderon M, Larenas D, Kleineâ€Tebbe J, Jacobsen L, Passalacqua G, Eng P, et al. European Academy of Allergy and Clinical Immunology task force report on 'dose–response relationship in allergenâ€specific immunotherapy'. Allergy. 2011; 66(10):1345-59. https://doi.org/10.1111/j.1398-9995.2011.02669.x PMid:21707645

Lee JH, Yu HH, Wang LC, Yang YH, Lin YT, Chiang BL. The levels of CD4+ CD25+ regulatory T cells in paediatric patients with allergic rhinitis and bronchial asthma. Clinical & Experimental Immunology. 2007; 148(1):53-63. https://doi.org/10.1111/j.1365-2249.2007.03329.x PMid:17349011 PMCid:PMC1868849

Maggi L, Santarlasci V, Liotta F, Frosali F, Angeli R, Cosmi L, et al. Demonstration of circulating allergen-specific CD4+ CD25highFoxp3+ T-regulatory cells in both nonatopic and atopic individuals. The Journal of allergy and clinical immunology. 2007; 120(2):429-36. https://doi.org/10.1016/j.jaci.2007.05.002 PMid:17604089

Sabin BR, Saltoun CA, Avila PC. Advances in upper airway diseases and allergen immunotherapy. Journal of Allergy and Clinical Immunology. 2011; 127(2):342-50. https://doi.org/10.1016/j.jaci.2010.11.049 PMid:21281864

Matricardi PM, Kuna P, Panetta V, Wahn U, Narkus A. Subcutaneous immunotherapy and pharmacotherapy in seasonal allergic rhinitis: a comparison based on meta-analyses. Journal of Allergy and Clinical Immunology. 2011; 128(4):791-9. e6.

Radulovic S, Jacobson MR, Durham SR, Nouri-Aria KT. Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. Journal of Allergy and Clinical Immunology. 2008; 121(6):1467-72. https://doi.org/10.1016/j.jaci.2008.03.013 PMid:18423565

Allan SE, Passerini L, Bacchetta R, Crellin N, Dai M, Orban PC, et al. The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs. Journal of Clinical Investigation. 2005; 115(11):3276-84. https://doi.org/10.1172/JCI24685 PMid:16211090 PMCid:PMC1242190

Bacchetta R, Gregori S, Roncarolo M-G. CD4+ regulatory T cells: Mechanisms of induction and effector function. Autoimmunity reviews. 2005; 4(8):491-6. https://doi.org/10.1016/j.autrev.2005.04.005 PMid:16214084

Cantillo JF, Puerta L. [New approaches for allergen-specific immunotherapy]. Biomedica: revista del Instituto Nacional de Salud. 2009; 30(3):440-53.

Chatila TA. Role of regulatory T cells in human diseases. Journal of allergy and clinical immunology. 2005; 116(5):949-59. https://doi.org/10.1016/j.jaci.2005.08.047 PMid:16275360

Crellin NK, Garcia RV, Levings MK. Flow cytometry-based methods for studying signaling in human CD4+ CD25+ FOXP3+ T regulatory cells. Journal of immunological methods. 2007; 324(1):92-104. https://doi.org/10.1016/j.jim.2007.05.008 PMid:17582431

Published
2018-07-16
How to Cite
1.
Kouzegaran S, Ali Zamani M, Faridhosseini R, Rafatpanah H, Rezaee A, Yousefzadeh H, Movahed R, Azad FJ, Tehrani H. Immunotherapy in Allergic Rhinitis: It’s Effect on the Immune System and Clinical Symptoms. Open Access Maced J Med Sci [Internet]. 2018Jul.16 [cited 2020Nov.27];6(7):1248-52. Available from: https://www.id-press.eu/mjms/article/view/oamjms.2018.264
Section
B - Clinical Sciences

Most read articles by the same author(s)